Detalhe da pesquisa
1.
A biomarker signature to predict complete response to itacitinib and corticosteroids in acute graft-versus-host disease.
Br J Haematol
; 198(4): 729-739, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35689489
2.
Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial.
Blood
; 135(20): 1739-1749, 2020 05 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-32160294
3.
A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer.
Breast Cancer Res Treat
; 134(1): 13-20, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22198412
4.
A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease.
Blood Adv
; 4(8): 1656-1669, 2020 04 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-32324888
5.
Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: a pilot study.
Mol Oncol
; 6(4): 437-44, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22687601
6.
Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.
J Clin Oncol
; 26(18): 2999-3005, 2008 Jun 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-18458039
7.
Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.
J Clin Oncol
; 26(34): 5544-52, 2008 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18955454